Identification of an alternative CD20 transcript variant in B cell malignancies coding for a novel protein associated to rituximab resistance Scientific category: Lymphoid Neoplasia Running title: ΔCD20-spliced mRNA and rituximab resistance
نویسندگان
چکیده
1 INSERM, UMR645, 25020 Besançon, France 2 Université de Franche-Comté, IFR133, 25020 Besançon, France 3 EFS-BFC, Immuno-Molecular Therapeutics Laboratory, 25020 Besançon, France 4 EFS-BFC, Clinical Biomonitoring Laboratory, 25020 Besançon, France 5 CHU Jean Minjoz, Oncology/Hematology Department, 25020 Besançon, France 6 INSERM UMR823, Université Joseph Fourier, Grenoble I, Grenoble France 7 French GOELAMS Group 8 CNRS UMR5239, Université Lyon I, service d’Hématologie Lyon Sud, Lyon, France 9 INSERM U748, Interactions Virus-Hôte et Maladies du Foie, Inserm U748, Université de Strasbourg, France
منابع مشابه
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms of inherited resistance, sensitive versus resistant individuals were selected from a survey of 9...
متن کاملFc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that resistance could be explained, in part, by internalization of rituximab (type I anti-CD20) from the surface of certain B-cell malignancies, thus limiting engagement of natural effectors and increasing mAb consumption. Internalization of rituxima...
متن کاملDown-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Although rituximab is a key molecular targeting drug for CD20-positive B-cell lymphomas, resistance to rituximab has recently been recognized as a considerable problem. Here, we report that a CD20-negative phenotypic change after chemotherapies with rituximab occurs in a certain number of CD20-positive B-cell lymphoma patients. For 5 years, 124 patients with B-cell malignancies were treated wit...
متن کاملDevelopment of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has significantly improved the treatment outcome of lymphoma patients. Via an elusive mechanism, a subpopulation of patients becomes unresponsive and/or relapses. To recapitulate various aspects of acquired resistance, rituximab-resistant (RR) clones were established from l...
متن کاملcephalon oncology The evolving role of multifunctional agents in lymphoid malignancies
The use of rituximab has improved response rates and survival in many histologies of B-cell non-Hodgkin’s lymphoma (NHL). However, it has become clear that some patients have an intrinsic resistance to rituximab, while many other patients develop resistance after an earlier response to rituximab. In most situations, the molecular cause of either innate or acquired resistance has not been elucid...
متن کامل